Jefferies Reiterates Buy Rating on Disc Medicine (IRON)

Jefferies analyst Roger Song reiterated a Buy rating and $111.00 price target on Disc Medicine (NASDAQ: IRON).

The analyst commented, "DISC-0974’s Ph1b oral presentation at ASH24 (12/8 Sun, 5PM PT), with full 6mo data across all dose cohorts including highest 100mg, is expected to show continued promising efficacy results superior to comps, and (+) safety data with few AEs that are not cardiovascular-related, that will differentiate it from comps/ current Tx. Co expects to provide guidance on Ph2 design at ASH investor event (12/8 Sun, 6PM PT) and is on track to initiate Ph2 by YE24."

For an analyst ratings summary and ratings history on Disc Medicine click here. For more ratings news on Disc Medicine click here.

Shares of Disc Medicine closed at $62.65 yesterday.

You May Also Be Interested In

• Rosenblatt Starts CoreWeave (CRWV) at Buy
• Microsoft (MSFT) PT Lowered to $400 at Stifel
• Bain to acquire a majority stake in Volkswagen's Everllence - FT